Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
Colorcon
AstraZeneca
McKinsey

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

NPLATE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Tradename: NPLATE
Patents:21
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for NPLATE
Recent Clinical Trials for NPLATE

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AmgenPhase 3
University Children's Hospital BaselPhase 4
University Hospital, Basel, SwitzerlandPhase 4

See all NPLATE clinical trials

Pharmacology for NPLATE

Company Disclosures: US Patents for NPLATE

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
Amgen NPLATE romiplostim INJECTABLE; SUBCUTANEOUS 125268 001 2008-08-22   Start Trial Amgen Inc. (Thousand Oaks, CA) 2018-10-23 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for NPLATE

These patents were identified by searching patent claims

Supplementary Protection Certificates for NPLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
25/2009 Austria   Start Trial PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
122009000039 Germany   Start Trial PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
SPC/GB09/035 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/035 GRANTED TO KIRIN-AMGEN INC. IN RESPECT OF THE PRODUCT ROMIPLOSTIM, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6361 DATED 20/04/2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 05/02/2024.
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Harvard Business School
McKesson
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.